C02/95% O2 atmosphere in the presence of hormone or drug. At the end of the incubation period, the tissue and medium were transferred to tubes and centrifuged
glandin synthesis inhibitor, indomethacin, and the Ca2+-antagonist, verapamil, could not counteract the increase in prolactin binding induced by prolactin treatment, nor could dibutyryl cyclic AMP alone mimic the response. These data suggest that prostaglandins, Ca2+ or cAMP do not mediate the alteration in receptor binding. Furthermore, inhibition of lysosome activity by chloroquine could not alone increase the prolactin binding in the control tissues, suggesting that up-regulation does not simply reflect a protective action of prolactin on receptor degradation.
The degree and the direction to which prolactin modulates the concentration of its membrane receptor in its target organs is still a source of controversy. In the rat, evidence has been pres¬ ented for an up-regulation (Dave & Witorsch 1985; Blankenstein et al. 1985) , a down-regula¬ tion (Barash et al. 1983) , and lack of effect (Kledzik et al. 1976; Amit et al. 1983) in vivo. In a preliminary publication, we recently reported both an apparent up-regulation and a down-regulation of the receptor in prostatic expiants which were dose-dependent (Rui et al. 1986 ). were then subjected to a receptor assay which has been reported elsewhere (Charreau et al. 1977a ), using 125l-h-PRL (specific activity µCi/µg). Values are expressed as percent specific binding, which is calculated as the difference between radiolabelled hormone bound to the membranes in the absence and presence of 500-fold excess of unlabelled hormone. The method of Lowry et al. (1951) Specificity studies Expiants were incubated with varying concentrations of o-PRL (0, 0.3, 0.6, 0.9, 1.5 and 3.0 µg/2 ml), r-PRL (0, 0.3, 0.6, 0.9, 3.0 µg/2 ml), and h-PRL (0, 0.3, 0.6, 0.9, 3.0 µg/2 ml). The o-PRL was purchased from Sigma Chemical Co (Missouri, USA), r-PRL was isolated from GH3-cells as described elsewhere (Gautvik 8c Kriz 1976) , binding values (geometric means ± SD) were 7.6% (6.6-8.6), 11.8% (10.2-13.6), 12.5% (10.6-14.7) and 13.4% (12.2-14.6) for controls, expiants treated with prolactin, prolactin plus indomethacin, and prolactin plus verapamil, respectively. Increasing doses of dibutyryl cAMP (range 5 x 10"6 -3 x 10"4 mol/1) in the absence of prolactin could not mimic the effect of the hormone (data not shown). The lysosomal inhibitor chloroquine, at a concentration of 10~4 mol/1, did not influence the levels of prolactin binding. Specific prolactin binding (geometric mean ± SD) was 5.6% (4.6 -6.7), 4.8% (3.8-6.2) and 9.7% (8.1-11.9) for controls, chloroquine-and prolactin-treated explants, respectively.
Discussion
In confirmation of our previous report (Rui et al. 1986 ), prolactin was shown to cause an increase in the concentration of its membrane receptor bind¬ ing sites in rat ventral prostate expiants, over a particular dose range. In the previous study, addition of the hormone at the start of the incuba¬ tion was associated with a lag period of 6-12 h before any clear difference from the controls could be discerned. In the present study, where a 6-h delay was introduced before the addition of prolactin (Fig. 1) (Rui et al. 1984 ). The present study implies that this positive effect of prolactin on its receptor is channelled through alternative biochemical pathways.
One possibility yet to be tested is that it may operate via the polyamine system, as suggested from work on the mammary gland (Rilemma 1980 (Amador et al. 1985; Klemcke et al. 1986 ), the liver (Arnit et al. 1984; Manni et al. 1978) , the mammary gland (Dijane 8c Durand 1977) , the lung (Amit et al. 1985) , the adrenal gland (Calvo et al. 1981) , and Leydig cell tumour (Rui et al. 1986 
